BioNTech SE
In the published model solve dated 2026-Q2, anchored at $89.83, BioNTech SE (BNTX) is priced for +8.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 24, 2026 from SEC EDGAR filings.
• BioNTech's entire market value is barely more than the cash and securities already sitting on its own balance sheet, which leaves the oncology pipeline as close to a free option as a large-cap biotech gets. • The COVID-19 vaccine line still accounts for 70% of trailing revenue and is shrinking fast, while adjusted research spending for 2026 is guided at €2.2 billion to €2.5 billion against total revenue guidance of €2.0 billion to €2.3 billion [Source: BioNTech Q1 2026 results, May 5, 2026].
Is BNTX overvalued? See what's priced in →
263 institutional managers reported holding BNTX in 13F filings for the quarter ended 2026-03-31. Together they hold about 20% of the company; the top 10 hold 12%. 40 opened new positions that quarter. Held by FMR (Fidelity), PRIMECAP Management, Dodge & Cox, among others. On the short side, 2.7M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (2.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BNTX has cut its share count 0.9% over the past five years. It pays a dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 24, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.